Race-specific drugs: regulatory trends and public policy
By David E. Winickoff and Osagie K. Obasogie,
Trends in Pharmacological Sciences
| 06. 04. 2008
Numerous articles and commentaries in the health literature recently have questioned the emergence of race as an increasingly powerful organizing principle in clinical medicine and pharmaceutical development [1,2]. Yet proposals for regulatory reform remain thin. Debate over racebased medicine crystallized around the FDA's June 2005 approval of BiDil, a drug approved to treat African-Americans with heart failure. Some saw BiDil as a dangerous example of marketing trumping science [3], whereas others heralded BiDil as a step towards eliminating racial disparities in health care [4]. One thing is clear: the BiDil debate has left major questions about how clinical trial design and drug regulation should engage this trend [5].
The need for new regulatory approaches to medicines with race-specific indications is growing more acute. A new trend towards designing and conducting clinical trials for race-specific medicines [6] carries serious implications for equitable access to pharmaceutical innovations. Under current policies FDA-approved racial indications might prevent certain groups from accessing certain drugs, even when there is little evidence to warrant such exclusion. Given the stakes of such exclusions for public health, new regulatory...
Related Articles
By Darren Incorvaia, Fierce Biotech | 05.28.2025
An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), extending a moratorium that was first proposed in the fallout of a Chinese researcher’s widely decried use of...
Last week, May 21–23, a broad range of experts gathered in Boston to discuss the future of powerful biotechnologies with the potential to change what it means to be human. The fourth in a series of international Summits on human genome editing, this event was organized by the Global Observatory for Genome Editing, which “seeks to expand the range of questions arising at the frontiers of emerging biotechnologies … and fosters international, interdisciplinary, and cross-sectoral dialogue.” Like previous Summits...
By Christine Fernando, Associated Press | 05.20.2025
Days after a bombing outside a Southern California fertility clinic, a White House official confirmed Tuesday that the Trump administration is reviewing a list of recommendations to expand access to in vitro fertilization.
President Donald Trump signed an executive order...
By Elizabeth Chuck, NBC News | 05.19.2025